NCT02955940 2025-12-17An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibIncyte CorporationPhase 2 Active not recruiting10 enrolled
NCT02419495 2025-06-04Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesM.D. Anderson Cancer CenterPhase 1 Terminated221 enrolled